Essex LLC’s Biogen BIIB Stock Holding History

Essex LLC’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-6,318	Closed	-$1.79M	–	174
2021 Q3	$1.79M	Buy	+6,318	New	+$2.07M	0.5%	65

Other funds holding BIIB

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Essex LLC's BIIB Position: Q4 2021 in Review

Essex LLC sold out of Biogen (BIIB) in Q4 2021, closing a stake of 6,318 shares — an estimated $1.79M sold.

Essex LLC first reported a position in BIIB in Q3 2021 and held it in 1 quarter. The position peaked at $1.79M in Q3 2021. 1,009 funds tracked by Wall St. Rank hold BIIB as of Q4 2021.

Essex LLC reported no remaining Biogen position as of Q4 2021 after selling out during the quarter.
Essex LLC sold 6,318 Biogen shares in Q4 2021, an estimated $1.79M.
Essex LLC first reported a position in Biogen in Q3 2021 and held it in 1 quarter.
Essex LLC's Biogen position peaked at $1.79M in Q3 2021.
1,009 funds tracked by Wall St. Rank held Biogen as of Q4 2021.

Based on Essex LLC's 13F filing for Q4 2021, filed 28 Jan 2022.